KR20260016503A - 암성 동통 예방 또는 치료용 조성물 - Google Patents
암성 동통 예방 또는 치료용 조성물Info
- Publication number
- KR20260016503A KR20260016503A KR1020257041808A KR20257041808A KR20260016503A KR 20260016503 A KR20260016503 A KR 20260016503A KR 1020257041808 A KR1020257041808 A KR 1020257041808A KR 20257041808 A KR20257041808 A KR 20257041808A KR 20260016503 A KR20260016503 A KR 20260016503A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- halogen atoms
- group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2023-086153 | 2023-05-25 | ||
| JP2023086153 | 2023-05-25 | ||
| PCT/JP2024/018940 WO2024242158A1 (ja) | 2023-05-25 | 2024-05-23 | がん性疼痛予防又は治療用組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260016503A true KR20260016503A (ko) | 2026-02-03 |
Family
ID=93589461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257041808A Pending KR20260016503A (ko) | 2023-05-25 | 2024-05-23 | 암성 동통 예방 또는 치료용 조성물 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4699608A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024242158A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260016503A (cg-RX-API-DMAC7.html) |
| CN (1) | CN121079089A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2024275598A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL324153A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025013810A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202508584A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024242158A1 (cg-RX-API-DMAC7.html) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5636481A (en) | 1979-06-21 | 1981-04-09 | Clin Midy | Aminopiperidine* its manufacture* intermediate and medicine |
| JPH07145166A (ja) | 1991-03-27 | 1995-06-06 | Sanofi Sa | 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用 |
| JP7090344B2 (ja) | 2017-06-28 | 2022-06-24 | 国立大学法人大阪大学 | セロトニン3受容体アゴニストによる疼痛の治療 |
-
2024
- 2024-05-20 TW TW113118625A patent/TW202508584A/zh unknown
- 2024-05-23 WO PCT/JP2024/018940 patent/WO2024242158A1/ja not_active Ceased
- 2024-05-23 KR KR1020257041808A patent/KR20260016503A/ko active Pending
- 2024-05-23 AU AU2024275598A patent/AU2024275598A1/en active Pending
- 2024-05-23 CN CN202480031574.7A patent/CN121079089A/zh active Pending
- 2024-05-23 EP EP24811164.3A patent/EP4699608A1/en active Pending
- 2024-05-23 JP JP2025522445A patent/JPWO2024242158A1/ja active Pending
-
2025
- 2025-10-22 IL IL324153A patent/IL324153A/en unknown
- 2025-11-19 MX MX2025013810A patent/MX2025013810A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5636481A (en) | 1979-06-21 | 1981-04-09 | Clin Midy | Aminopiperidine* its manufacture* intermediate and medicine |
| JPH07145166A (ja) | 1991-03-27 | 1995-06-06 | Sanofi Sa | 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用 |
| JP7090344B2 (ja) | 2017-06-28 | 2022-06-24 | 国立大学法人大阪大学 | セロトニン3受容体アゴニストによる疼痛の治療 |
Non-Patent Citations (9)
| Title |
|---|
| Janette Nallely Corona-Ramos et al, The effect of Gabapentin and Tramadol in Cancer Pain Induced by Glioma Cell in Rat Femur, Drug Development Research, 2017년, 제78권, 173-183페이지 |
| Mohammad Zafar Imam et al, Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain, Pharmacological Reports, 2020년 7월 26일, 제72권, 1418-1425페이지 |
| Mohammed El Mouedden et al, Pharmacological evaluation of opioid and non-opioid analgesis in a murine bone cancer model of pain, Pharmacology, Biochemistry and Behavior, 2007년 1월 12일, 제86권, 458-467페이지 |
| Osamu Saito et al, Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain, Journal of Anesthesia, 2005년, 제19권, 218-224페이지 |
| Simeng Ma et al, Amitriptyline influences the mechanical withdrawal threshold in bone cancer pain rats by regulating glutamate transporter GLAST, Molecular Pain, 2019년, 제15권, 1-12페이지 |
| Tansy Donovan-Rodriguez et al, Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-induced Bone Pain, Anesthesiology, 2005년, 제102권, 132-140페이지 |
| 기타노 유타카(北野裕) 등, 일본약리지, 2019년, 제154권, 352-361페이지 |
| 바아트리스제약가부시키가이샤, 리리카(등록상표) 캡슐 및 OD정의 25mg, 75mg 및 150mg의 첨부 문서, 2022년 7월 개정(제3판) |
| 의료용마약 적정사용가이던스 후생노동성 의약·생활 위생국 감시지도·마약대책과 2017년 4월 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202508584A (zh) | 2025-03-01 |
| EP4699608A1 (en) | 2026-02-25 |
| AU2024275598A1 (en) | 2026-01-15 |
| CN121079089A (zh) | 2025-12-05 |
| WO2024242158A1 (ja) | 2024-11-28 |
| MX2025013810A (es) | 2025-12-01 |
| IL324153A (en) | 2025-12-01 |
| JPWO2024242158A1 (cg-RX-API-DMAC7.html) | 2024-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10952976B2 (en) | Compositions and methods for treating respiratory depression with fenfluramine | |
| US8653033B2 (en) | Method for administering omega-conopeptide | |
| KR102489052B1 (ko) | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 | |
| JP2005522445A (ja) | 注意欠陥過活動性障害(ad/hd)の処置方法 | |
| CN117177772A (zh) | 伴有饥饿素抵抗性的恶病质的治疗剂或预防剂 | |
| WO2024242158A1 (ja) | がん性疼痛予防又は治療用組成物 | |
| WO2007040535A1 (en) | Use of polyamine analogs for treatment and prevention of intestinal polyps | |
| CN103002893A (zh) | 神经障碍性疼痛的治疗药或预防药 | |
| CA3289710A1 (en) | Composition for preventing or treating cancer pain | |
| JP7090344B2 (ja) | セロトニン3受容体アゴニストによる疼痛の治療 | |
| EP3087984B1 (en) | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder | |
| US20220024976A1 (en) | Salt and crystalline forms of rapastinel | |
| KR101779135B1 (ko) | 덱사메타손과 이부프로펜을 유효성분으로 포함하는 신경병증성 통증 예방 및 치료용 약학적 조성물 | |
| JPWO2005089742A1 (ja) | 頻尿または尿失禁の予防または治療用医薬 | |
| JP2005314313A (ja) | 過敏性腸症候群を予防又は治療するための医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |